# First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

> **NCT06097455** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Fundacion Clinic per a la Recerca Biomédica** · enrollment: 40 (estimated)

## Conditions studied

- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma

## Interventions

- **GENETIC:** ARI0003

## Key facts

- **NCT ID:** NCT06097455
- **Lead sponsor:** Fundacion Clinic per a la Recerca Biomédica
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01-15
- **Primary completion:** 2025-04-15
- **Final completion:** 2027-01-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06097455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06097455, "First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06097455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*